Catherine Wood's TEVA Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 105,131 shares of Teva Pharmaceutical Industries Limited (TEVA) worth $3.28 M, representing 0.02% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 320,042 shares. Largest reduction occurred in Q3 2021, reducing 108,446 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -13,590 | Reduce 11.45% | 105,131 | $31.21 |
| Q3 2025 | -2,153 | Reduce 1.78% | 118,721 | $20.20 |
| Q2 2025 | +30,621 | Add 33.93% | 120,874 | $16.76 |
| Q1 2025 | -10,190 | Reduce 10.15% | 90,253 | $15.37 |
| Q4 2024 | -23,422 | Reduce 18.91% | 100,443 | $22.04 |
| Q3 2024 | -45,555 | Reduce 26.89% | 123,865 | $18.02 |
| Q2 2024 | -22,716 | Reduce 11.82% | 169,420 | $16.25 |
| Q1 2024 | -30,670 | Reduce 13.77% | 192,136 | $14.11 |
| Q4 2023 | -32,004 | Reduce 12.56% | 222,806 | $10.44 |
| Q3 2023 | +16,887 | Add 7.10% | 254,810 | $10.20 |
| Q2 2023 | +26,145 | Add 12.35% | 237,923 | $7.53 |
| Q1 2023 | -47,385 | Reduce 18.28% | 211,778 | $8.85 |
| Q4 2022 | -76,305 | Reduce 22.75% | 259,163 | $9.12 |
| Q3 2022 | +102,950 | Add 44.28% | 335,468 | $8.07 |
| Q2 2022 | -67,494 | Reduce 22.50% | 232,518 | $9.10 |
| Q1 2022 | -4,780 | Reduce 1.57% | 300,012 | $9.39 |
| Q4 2021 | -99,204 | Reduce 24.56% | 304,792 | $8.01 |
| Q3 2021 | -108,446 | Reduce 21.16% | 403,996 | $9.74 |
| Q2 2021 | +12,598 | Add 2.52% | 512,442 | $9.90 |
| Q1 2021 | +320,042 | Add 178.00% | 499,844 | $11.54 |
| Q4 2020 | +104,715 | Add 139.46% | 179,802 | $9.65 |
| Q3 2020 | -24,905 | Reduce 24.91% | 75,087 | $9.02 |
| Q2 2020 | +43,869 | Add 78.17% | 99,992 | $12.33 |
| Q1 2020 | +9,994 | Add 21.67% | 56,123 | $8.98 |
| Q4 2019 | -10,569 | Reduce 18.64% | 46,129 | $9.80 |
| Q3 2019 | +22,291 | Add 64.79% | 56,698 | $6.88 |
| Q2 2019 | +9,945 | Add 40.65% | 34,407 | $9.24 |
| Q1 2019 | +856 | Add 3.63% | 24,462 | $15.70 |
| Q4 2018 | +543 | Add 2.35% | 23,606 | $15.42 |
| Q3 2018 | -7,424 | Reduce 24.35% | 23,063 | $21.55 |
| Q2 2018 | +2,561 | Add 9.17% | 30,487 | $24.31 |
| Q1 2018 | +10,762 | Add 62.70% | 27,926 | $17.08 |
| Q4 2017 | +17,165 | Add 0.00% | 17,164 | $18.93 |
Catherine Wood's Teva Pharmaceutical Industries Limited Investment FAQs
Catherine Wood first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2017, acquiring 17,164 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Teva Pharmaceutical Industries Limited (TEVA) for 33 quarters since Q4 2017.
Catherine Wood's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q1 2021, adding 499,844 shares worth $5.77 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 105,131 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $3.28 M.
As of the Q4 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.02% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 512,442 shares, as reported at the end of Q2 2021.